Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Compuesto yodado para proteger la salud de lesiones causadas por radiación nuclear como cápsula de administración oral

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180810002
Publicado:
30/08/2018
Caducidad:
31/08/2019
Resumen:
Una empresa francesa con amplia experiencia en la industria farmacéutica ha obtenido la patente de una preparación para proteger la salud que se presenta como una cápsula de gelatina blanda con calidad de medicamento. Una sola dosis administrada por vía oral dos veces al año ofrece una cobertura preventiva de la glándula tiroides contra el cáncer durante seis meses en caso de accidente nuclear. La patente describe la preparación de ésteres de ácidos grasos yodados que contienen cantidades específicas de ésteres de ácido monoiodoestearato, como ésteres etílicos de ácidos grasos procedentes de aceites vegetales, y en particular aceite de colza. La empresa busca laboratorios farmacéuticos con el fin de establecer acuerdos de licencia, cooperación y comercialización con asistencia técnica.

Details

Tittle:
Iodinated compound for health protection from nuclear radiation injury as capsule for oral administration
Summary:
A French company with deep pharmaceutical expertise has patented the preparation of an organism-protecting product, of medicament quality, as soft-gelatin capsule. A single dose is administrated orally every twice a year, allowing preventive coverage for the thyroid gland from cancer for 6 months in case of a nuclear accident.
Pharmaceutical labs are sought for licensing, technical cooperation, commercial agreement with technical assistance.
Description:
During a nuclear accident, explosion can be followed by rejecting radioactive iodine in the air. The effectiveness of iodide derivate as a specific blocker of thyroid radioiodine uptake is well established by the Authorities. When administered in the recommended dose, iodide derivative is effective in reducing the risk of thyroid cancer in individuals or populations at risk for inhalation or ingestion of radioiodines after nuclear accident. Actually, only iodide as potassium iodide tablets are marketed. For this product, timing is crucial in this matter, given that the tablets are only effective for 24 hours.
An iodized product must then be available for the populations exposed to guarantee their safety, specially from thyroid cancer, and with a maximum of efficiency.

The french company specialized in pharmaceutical expertises and development for more than 30 years, has patented a preparation with soft-gelatin capsule product.

The aim of this patented compound, being taken twice a year ensures a long protection against radioactive iodine. Indeed, the organic iodide compound, administered by a single dose will not be eliminated quickly but will be stored in organism followed by a progressive metabolisation by human. The patend describes the preparation of iodinated fatty acid esters containing specific amounts of monoiodostearic acid esters as ethyl esters of fatty acids originated from vegetal oils, in particular rapeseed oil. The finished product is then constituted of iodinated oil alone or in combination with excipients in a soft-gelatin capsule. Due to the particular composition of fatty acids of the patented product, the release and metabolisation of iodine from iodinated oil is performed during at least 6 months.

They are looking for industrial partner for the finalization of the finished product and regulatory file prior marketing.
They are interested by pharmaceutical laboratory with development ressources in order to industrialise patented synthesis in the frame of licence agreement, technical cooperation with technical assistance.
Advantages and Innovations:
Innovation :
- a single dose of the product is orally administrated twice a year, allows preventive coverage for the thyroid gland from cancer during 6 months in case of nuclear accident
- patented synthesis uses conventional and classical reagents and equipment
- reduced cost for a oral single-dose administrated every six months

Advantages
- as the patented product will be administrated twice a year, population can be more efficiency protected as no emergency administration will be need in case of nuclear accident
- protection will be more efficiency compared to potassium iodide already marketed and which offers only 24 hours protection
- lower toxicity as this product can be administrated to young and older population
- no potassium administration as for already marketed potassium iodine tablets
Stage of Development:
Under development/lab tested
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
Type of partner : pharmaceutical laboratory with development ressources in order to industrialise patented synthesis

Area of activities : pharmaceutical development

Tasks to be done : raw material synthesis following patented scheme synthesis. Finished product batches to perform and regulatory files.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French

Dissemination

Restrict dissemination to specific countries:
Albania, Austria, Belarus, Belgium, Bosnia And Herzegovina, Bulgaria, Croatia, Czech_Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithuania, Luxembourg, Moldova, Republic Of, Montenegro, Netherlands, Norway, Poland, Portugal, Republic of Serbia, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom

Keywords

Technology Keywords:
04004 Fisión nuclear / fusión nuclear
06001008 Medicina medioambiental, medicina social, medicina deportiva
03004007 Pharmaceutics
10001005 Protección contra la radiación
06001006 Vacunas humanas